Immune-Onc Therapeutics - About the company
Immune-Onc Therapeutics is a series B company based in Palo Alto (United States), founded in 2016 by Charlene Liao. It operates as a Developer of antibodies to target immune system and tumor microenvironment. Immune-Onc Therapeutics has raised $138M in funding from investors like NLVC, CLI Ventures and StartX. The company has 3295 active competitors, including 1129 funded and 779 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of antibodies to target the immune system and tumor microenvironment. The company has developed drug candidates by targeting Leukocyte Immunoglobulin-like Receptor subfamily B (LILRB) of myeloid checkpoints to overcome immune resistance. The product pipeline includes I0-202 for acute myeloid leukemia, I0-108 for solid tumors, and hematologic malignancies.
- Website
- www.immune-onc.com/
- Social
- Email ID
- *****@immuneonc.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2016
Location
Palo Alto, United States
Stage
Series B
Total Funding
$138M in 5 rounds
Latest Funding Round
Ranked
931st among 3295 active competitors
Employee Count
12 as on Aug 31, 2026
Similar Companies
Legal entities associated with Immune-Onc Therapeutics
Immune-Onc Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Immune-Onc Therapeutics, Inc. CIN: 81-2180798 , United States, Active | Mar 21, 2016 | - | 24 (As on Dec 31, 2022) | - |
Sign up to download Immune-Onc Therapeutics' company profile
Immune-Onc Therapeutics's funding and investors
Immune-Onc Therapeutics has raised a total funding of $138M over 5 rounds. Its first funding round was on Sep 21, 2016. Its latest funding round was a Series B round on Jan 05, 2023 for $*****. 4 investors participated in its latest round. Immune-Onc Therapeutics has 21 institutional investors.
Here is the list of recent funding rounds of Immune-Onc Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 05, 2023 | 4904167 | Series B | 6651868 | 5490414 | 1368941 | 9912158 |
Mar 30, 2021 | 4121396 | Series B | 8269777 | 1186671 | 7684448 | |
Aug 01, 2020 | 4861101 | Grant (prize money) | 4022446 | 9075050 | 3702322 |
Access funding benchmarks and valuations. Sign up today!View details of Immune-Onc Therapeutics's funding rounds and investors
Immune-Onc Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Immune-Onc Therapeutics is Charlene Liao. Charlene Liao is the CEO of Immune-Onc Therapeutics.
Here are the details of Immune-Onc Therapeutics' key team members:
- Charlene Liao: Founder & CEO & President of Immune-Onc Therapeutics.
View details of Immune-Onc Therapeutics's Founder profiles and Board Members
Immune-Onc Therapeutics' employee count trend
Immune-Onc Therapeutics has 12 employees as of Aug 26. Here is Immune-Onc Therapeutics's employee count trend over the years:
Uncover Immune-Onc Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immune-Onc Therapeutics's Competitors and alternates
Top competitors of Immune-Onc Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Immune-Onc Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
931st | Immune-Onc Therapeutics 2016, Palo Alto (United States), Series B | Developer of antibodies to target immune system and tumor microenvironment | $138M | 44/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immune-Onc Therapeutics's competitors? Click here to see the top ones
Immune-Onc Therapeutics's Investments and acquisitions
Immune-Onc Therapeutics has made no investments or acquisitions yet.
Reports related to Immune-Onc Therapeutics
Here is the latest report on Immune-Onc Therapeutics's geography:
News related to Immune-Onc Therapeutics
Filter this list•
•
•
•
•
•
Immune-Onc’s antibody therapy collects second FDA orphan designationPharmaceutical Technology•Feb 22, 2024•Immune-Onc Therapeutics
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immune-Onc Therapeutics
Explore our recently published companies
- ReFrame Engage - United States based, 2020 founded, Unfunded company
- Web Instant Messenger - Bolzano based, 2016 founded, Unfunded company
- Carekro - 2018 founded, Unfunded company
- Dnyhospitality - Unfunded company
- Doral SEO - Doral based, 2026 founded, Unfunded company
- EMJ - Italy based, 2026 founded, Unfunded company
